Table 7.
Sex-specific clinical outcomes for subgroupstratified by 55 years in COVID-19 patients.
| Clinical outcomes | Age ≤ 55 Y (n = 255) | Age > 55 Y (n = 158) | ||||
|---|---|---|---|---|---|---|
| Male (n = 149) | Female (n = 106) | P-value | Male (n = 81) | Female (n = 77) | P-value | |
| Disease severity | ||||||
| Non-severe | 128 (85.9) | 93 (87.7) | – | 46 (56.8) | 55 (71.4) | – |
| Severe | 21 (14.1) | 13 (12.3) | 0.672 | 35 (43.2) | 22 (28.6) | 0.055 |
| ARDS | 25 (16.8) | 14 (13.2) | 0.435 | 37 (45.7) | 26 (33.8) | 0.126 |
| Time from symptom onset to ARDS, Median (IQR), d | 9 (7, 12) | 11 (7, 16) | 0.181 | 13 (8, 17) | 12 (8, 16) | 0.484 |
| Sepsis shock | 1 0 (6.7) | 7 (6.6) | 0.973 | 12 (14.8) | 5 (6.5) | 0.092 |
| Time from symptom onset to shock, Median (IQR), d | 17 (11, 20) | 23 (14, 33) | 0.244 | 18 (14, 25) | 18 (13, 23) | 0.828 |
| AKI | 5 (3.4) | 4 (3.8) | 0.859 | 13 (16.0) | 6 (7.8) | 0.111 |
| Time from symptom onset to AKI, Median (IQR), d | 20 (13, 22) | 22 (21, 23) | 0.438 | 16 (13, 22) | 18 (14, 26) | 0.374 |
| Acute liver injury | 13 (8.7) | 10 (9.4) | 0.846 | 20 (24.7) | 8 (10.4) | 0.019 |
| Time from symptom onset to acute liver injury, Median (IQR), d | 13 (10, 16) | 13 (8, 22) | 0.657 | 16 (13, 22) | 17 (12, 23) | 0.972 |
| Acute cardiac injury | 10 (6.7) | 5 (4.7) | 0.505 | 21 (25.9) | 7 (9.1) | 0.006 |
| Time from symptom onset to acute cardiac injury, Median (IQR), d | 15 (10, 18) | 18 (17, 21) | 0.145 | 16 (11, 23) | 14 (9, 22) | 0.202 |
| In-hospital mortality | 6 (4.0) | 4 (3.8) | 0.918 | 17 (21.0) | 4 (5.2) | 0.007 |
Data are n (%) unless specified otherwise. P < 0.05 was considered statistically significant. COVID-19, coronavirus disease 2019; ARDS, acute respiratory distress syndrome; IQR, inter quartile range; AKI, acute kidney injury. Bold value means P < 0.05.